Trade Secrets in Life Sciences: Protecting What You Cannot — or Choose Not to — Patent

In the architecture of a life sciences startup’s intellectual property strategy, trade secrets occupy a distinctive and sometimes underestimated position. Unlike patents, which require public disclosure of an invention in exchange for a time-limited period of exclusivity, trade secrets derive their value entirely from remaining confidential — and they can, in principle, provide protection that lasts indefinitely, as long as the information remains secret and continues to provide a competitive advantage. For life sciences companies, where the path from discovery to commercialized product involves years of accumulated know-how, process optimization, analytical methods, formulation expertise, and clinical insight, the body of proprietary information that qualifies for trade secret protection is often far larger than founders initially appreciate. A thoughtful trade secret strategy that identifies the company’s most valuable confidential information, implements appropriate measures to protect it, and integrates seamlessly with the patent strategy, can provide a layer of competitive protection that persists long after patents have expired and that is invisible to competitors in ways that patents, by definition, cannot be.

What Qualifies as a Trade Secret

The legal definition of a trade secret, while varying somewhat across jurisdictions, shares common core elements that provide a practical framework for identifying protectable information. In the United States, the Defend Trade Secrets Act, the federal statute that governs trade secret protection at the national level, defines a trade secret as information of any kind that derives independent economic value from not being generally known or readily ascertainable by others who could exploit its commercial value, and that is the subject of reasonable measures to maintain its secrecy. State trade secret laws, most of which are based on the Uniform Trade Secrets Act, apply similar standards. The breadth of what can qualify as a trade secret under these definitions is substantial. In the life sciences context, protectable trade secrets can include proprietary manufacturing processes and process parameters, cell line development and characterization data, formulation compositions and methods, analytical testing methods and specifications, regulatory strategy and submission know-how, clinical trial data and patient outcomes information, pricing and reimbursement strategies, supplier and vendor relationships, and the identity of research targets and development programs that have not yet been disclosed publicly. The common thread across all these categories is that the information has commercial value precisely because it is not known to competitors. The moment it becomes generally known or readily ascertainable, its status as a trade secret is lost.

Trade Secrets Versus Patents: Choosing the Right Protection

One of the most important strategic decisions a life sciences startup must make with respect to any significant piece of proprietary information is whether to seek patent protection, rely on trade secret protection, or pursue both in a coordinated manner. The choice is consequential and, in many cases, irreversible. Filing a patent application requires public disclosure of the invention, which permanently destroys the possibility of trade secret protection for the disclosed information. Several factors should inform this decision. Patent protection is generally preferable when the invention can be clearly defined in claims, when the period of exclusivity provided by a patent is sufficient to justify the investment in prosecution, when the invention could be independently discovered or reverse engineered by a competitor, and when the patent will provide enforcement rights that trade secret law cannot. Trade secret protection is generally preferable when the information cannot be adequately claimed in a patent, when the competitive advantage it provides is likely to outlast the term of a patent, when the information relates to a process or method that cannot be detected or reverse engineered from the commercial product, and when the cost and disclosure requirements of patent prosecution are disproportionate to the protection that would be obtained. In the pharmaceutical manufacturing context, for example, a proprietary cell culture process or purification method that is not discernible from the final product and that provides a meaningful cost or quality advantage may be far more valuable as a trade secret than as a patent. A patent would require public disclosure of the process while providing only twenty years of protection, whereas a trade secret could maintain competitive advantage indefinitely.

The Reasonable Measures Requirement: Building a Trade Secret Protection Program

The most critical distinction between trade secret protection and other forms of IP is that trade secret rights do not arise automatically. They must be actively created and maintained through the implementation of reasonable measures to keep the information secret. This requirement is not merely a legal technicality; it is the foundation upon which all trade secret protection rests, and a company that fails to implement and document appropriate secrecy measures may find that its purported trade secrets are unprotectable when it most needs to enforce them. What constitutes reasonable measures will depend on the nature of the information, the size and resources of the company, and the industry context. However, in the life sciences setting, a robust trade secret protection program will typically include several core elements. Physical and digital access controls should limit access to confidential information to those who genuinely need it, with access logs that document who has accessed sensitive information and when. Confidentiality and non-disclosure agreements should be executed with every employee, consultant, contractor, collaborator, and business partner before any confidential information is shared, and these agreements should be specific enough to put the recipient on clear notice of what information is considered confidential. Information should be clearly labeled as confidential or proprietary, both in physical form and in digital systems, so that recipients cannot later claim ignorance of its confidential status. Exit procedures for departing employees should include reminders of continuing confidentiality obligations, the return or destruction of confidential materials, and documentation that these steps have been completed.

Employee Agreements and the Protection of Human-Embodied Know-How

In life sciences companies, a significant portion of the most valuable trade secret information is not contained in documents or databases but is embodied in the knowledge, skills, and expertise of key scientific personnel, such as the process engineer who has spent years optimizing a manufacturing method, the formulation scientist who understands intuitively how to achieve stability in a challenging biological product, or the regulatory affairs professional who has developed deep expertise in navigating a complex approval pathway. Protecting this human-embodied know-how presents unique challenges because employees are free to carry their general knowledge and skills with them when they leave. Trade secret law protects specific confidential information, not general expertise acquired through experience. The primary legal tools for managing this risk are the invention assignment agreement, the confidentiality agreement, and in appropriate circumstances the non-compete or non-solicitation agreement. Invention assignment agreements, as discussed in the inventorship section of this guide, ensure that inventions made by employees in the course of their employment belong to the company. Confidentiality agreements impose ongoing obligations that survive the employment relationship, requiring former employees to maintain the confidentiality of information they acquired during their tenure. Non-compete agreements, which restrict a departing employee’s ability to work for competitors for a defined period, can provide an additional layer of protection for the most sensitive trade secret information, but their enforceability varies significantly across jurisdictions. Some states, including California, effectively prohibit them, making it essential to work with employment counsel to understand what protections are available and enforceable in the relevant jurisdiction.

Managing Trade Secrets in Collaborative Research

Life sciences startups routinely engage in collaborative research with universities, contract research organizations, contract manufacturing organizations, and industry partners. Each of these relationships creates potential vulnerabilities in the trade secret protection program that must be actively managed. Before any confidential information is shared with an outside party, a written confidentiality agreement should be in place that clearly defines what information is being shared, how it may be used, what obligations the recipient has to maintain its confidentiality, and what happens to the information upon termination of the relationship. In practice, many research collaborations begin with a mutual non-disclosure agreement that provides reciprocal protection for both parties’ confidential information, establishing the legal framework within which the scientific exchange can take place. However, a generic NDA is often insufficient to address the specific circumstances of a life sciences research collaboration. The agreement should be tailored to address questions such as whether the recipient may share the information with subcontractors or sublicensees, whether the information may be used for purposes beyond the specific collaboration, how long the confidentiality obligations last, and what happens to materials and data generated in the collaboration upon its conclusion. In collaborations with universities, additional complexity arises from the academic culture of open publication. Researchers at academic institutions have strong professional incentives to publish their findings, and this publication imperative can conflict directly with the startup’s interest in maintaining trade secret protection. Collaboration agreements with academic institutions should address publication rights explicitly, typically by providing for a review period before publication during which the startup can identify patentable inventions and request delays sufficient to allow patent applications to be filed.

Trade Secrets in Manufacturing and Scale-Up

For life sciences companies developing biological products, including monoclonal antibodies, recombinant proteins, cell therapies, and gene therapies, the manufacturing process is frequently as valuable as the product itself, and trade secret protection for manufacturing know-how can be among the most commercially significant IP assets a company holds. The development of a robust, scalable, and cost-effective manufacturing process for a complex biological product requires years of painstaking optimization work involving cell line development, media formulation, process parameters, purification methods, and analytical characterization — work that creates an enormous body of proprietary know-how that may not be fully protectable through patents but that provides a durable competitive advantage when properly protected as a trade secret. This manufacturing know-how is particularly valuable in the biosimilars context. A biosimilar manufacturer seeking to develop a competing product must independently develop its own manufacturing process, and the accumulated process knowledge of the innovator company, if properly protected, cannot be simply copied even when the product’s sequence and structure are known. Protecting manufacturing trade secrets requires not only strong confidentiality agreements with contract manufacturing partners but also careful management of the information shared with those partners, sharing only what is necessary for the manufacturing relationship, retaining control of critical process parameters where possible, and ensuring that agreements with contract manufacturing organizations (CMOs) clearly address ownership of process improvements and the return or destruction of confidential information upon termination.

Integrating Trade Secret Strategy with the Broader IP Program

The most effective trade secret strategy for a life sciences startup is not developed in isolation but is integrated from the outset with the company’s patent strategy, its employment practices, its collaborative research arrangements, and its overall approach to information security. At the portfolio level, this means making deliberate decisions about which information to patent and which to protect as a trade secret, rather than defaulting to one approach or the other without analysis. It means ensuring that the decision to file a patent application, which will ultimately result in public disclosure, is made with full awareness of the trade secret implications, and that information intended for trade secret protection is kept out of patent applications and other public disclosures. It means building a culture of confidentiality within the organization, where employees understand the value of the company’s proprietary information and their obligations to protect it, and where the processes and systems for managing confidential information are robust enough to withstand scrutiny in litigation if misappropriation ever occurs. And it means treating the trade secret protection program not as a one-time exercise but as an ongoing management responsibility that evolves as the company grows, as new information is created, as new collaborations are formed, and as the competitive landscape changes. For life sciences startups that get this right, trade secrets can provide a durable and commercially significant competitive advantage that complements the patent portfolio, survives patent expiration, and contributes meaningfully to the long-term value of the enterprise.

This article is part of our Life Sciences Startup IP Resource Center.